Dillon M. Voss
Education:
B.S. California University of Pennsylvania (2013)
M.S. Case Western Reserve University (2017)
Ph.D. Stony Brook University (2024)
Current Position:
7th Year MSTP
3rd Year Medical Student
Advisor:
Adrian Krainer, CSHL
Graduate Program:
Genetics
Research Interest:
My broad research interests include studying how the tumor microenvironment alters and maintains cancer stem cell (CSC) signaling pathways, as well as integrating omics-driven research with bioinformatics to improve how tumors are characterized and treated. My previous work mainly involved studying the hypoxic tumor microenvironment of high-grade gliomas, and identifying small molecule compounds that disrupted various signaling nodes of common CSC maintenance pathways. I look forward to developing a more translational approach to my research, with hopes to both assist cancer patients as they navigate clinical trials, as well as use these experiences to guide my search for new therapies.
Publications:
#Voss DM, Kral AJ, Utama R, Lin K, Cizmeciyan C, Schafer B, et al. PKM splice-switching ASOs induce upregulation of dual-specificity phosphatases and dephosphorylation of ERK1/2 in hepatocellular carcinoma. J. Biol. Chem. 2024;(In Resubmission).
#Wan L, Kral AJ, Voss DM, Schäfer B, Sudheendran K, Danielsen M, et al. Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids. Nucleic Acid Ther. 2024;34(4):188-98.
#Ma WK, Voss DM, Scharner J, Costa ASH, Lin K-T, Jeon HY, et al. ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth. Cancer Research. 2022;82(5):900-15.
#Kim YJ, Sivetz N, Layne J, Voss DM, Yang L, Zhang Q, et al. Exon-skipping antisense oligonucleotides for cystic fibrosis therapy. PNAS. 2022;119(3):e2114858118.
Voss DM, Sloan A, Spina R, Ames HM, Bar EE. The Alternative Splicing Factor, MBNL1, Inhibits Glioblastoma Tumor Initiation and Progression by Reducing Hypoxia-Induced Stemness. Cancer Res. 2020;80(21):4681-92.
Spina R, Voss DM, Yang X, Sohn JW, Vinkler R, Schraner J, et al. MCT4 regulates de novo pyrimidine biosynthesis in GBM in a lactate-independent manner. Neurooncol Adv. 2020;2(1):vdz062.
Spina R, Voss DM, Asnaghi L, Sloan A, Bar EE. Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells. J Vis Exp. 2018(131).
Voss DM, Spina R, Carter DL, Lim KS, Jeffery CJ, Bar EE. Disruption of the monocarboxylate transporter-4-basigin interaction inhibits the hypoxic response, proliferation, and tumor progression. Sci Rep. 2017;7(1):4292.
Spina R, Voss DM, Asnaghi L, Sloan A, Bar EE. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget. 2016;7(1):459-72.
* Both authors contributed equally to this work.
# Indicates publication during MSTP training.
